Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Checkpoint blockade: a concept or already a reality?

Emerging pathways in immunotherapy

Recent advances in mantle cell lymphoma: Expert panel discussion

Lecture: PSA Screening - Where East meets West

Lecture: Current use of systemic therapies in localised disease

Lecture: Current standard of care in advanced disease

Lecture: Exploring the androgen signalling pathway in CRPC

Lecture: Clinical perspectives: Non-AR therapeutic targets in CRPC

Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (for)